Tocilizumab 20 MG/ML
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sars-CoV2
Conditions
Sars-CoV2
Trial Timeline
Jun 1, 2020 → Dec 31, 2025
NCT ID
NCT04363853About Tocilizumab 20 MG/ML
Tocilizumab 20 MG/ML is a phase 2 stage product being developed by Roche for Sars-CoV2. The current trial status is active. This product is registered under clinical trial identifier NCT04363853. Target conditions include Sars-CoV2.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04363853 | Phase 2 | Active |
Competing Products
3 competing products in Sars-CoV2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Remdesivir | Gilead Sciences | Pre-clinical | 22 |
| IMM-BCP-01 + Placebo | Immunome | Phase 1 | 28 |
| VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3 | Vaxart | Phase 2 | 44 |